Onderneming Ultragenyx Pharmaceutical Inc.
Aandelen
RARE
US90400D1081
Biotechnologie & Medisch Onderzoek
Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
45,5 USD | +4,15% | +7,28% | -5,08% |
01:11 | ULTRAGENYX PHARMACEUTICAL INC. : RBC Capital Markets herhaalt koopadvies | ZM |
15/04 | Transcript : Ultragenyx Pharmaceutical Inc. - Special Call |
Vakgebied
Aantal werknemers: 1 276
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Crysvita Royalty
42,1
%
| 22 | 6,0 % | 183 | 42,1 % | +742,02% |
Crysvita
17,4
%
| 43 | 11,7 % | 76 | 17,4 % | +77,37% |
Dojolvi
16,3
%
| 56 | 15,3 % | 71 | 16,3 % | +27,01% |
Collaboration and License - Crysvita Collaboration Revenue in Profit-share Territory
16,1
%
| 215 | 59,2 % | 70 | 16,1 % | -67,58% |
Mepsevii
7,0
%
| 21 | 5,7 % | 30 | 7,0 % | +47,51% |
Evkeeza
0,8
%
| - | - | 4 | 0,8 % | - |
Collaboration and License - Daiichi Sankyo
0,3
%
| 8 | 2,1 % | 1 | 0,3 % | -80,76% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
North America
70,7
%
| 281 | 77,4 % | 307 | 70,7 % | +9,27% |
Latin America
17,8
%
| 45 | 12,3 % | 77 | 17,8 % | +72,98% |
Europe
10,9
%
| 36 | 10,0 % | 48 | 10,9 % | +30,70% |
Japan
0,5
%
| 1 | 0,3 % | 2 | 0,5 % | +91,56% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Emil Kakkis
FOU | Founder | 63 | 22-04-10 |
Howard Horn
DFI | Director of Finance/CFO | 47 | 16-10-23 |
Eric Crombez
CTO | Chief Tech/Sci/R&D Officer | - | 01-11-17 |
Dennis Huang
CTO | Chief Tech/Sci/R&D Officer | 59 | 01-05-15 |
Chief Tech/Sci/R&D Officer | 75 | 01-11-17 | |
Joshua Higa
IRC | Investor Relations Contact | - | - |
Ernie Meyer
HRO | Human Resources Officer | 60 | 01-09-20 |
Karah Parschauer
LAW | General Counsel | 46 | 20-06-16 |
Vimal Srivastava
PRN | Corporate Officer/Principal | 58 | 01-08-11 |
Erik Harris
PRN | Corporate Officer/Principal | 54 | 01-01-17 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Deborah Dunsire
BRD | Director/Board Member | 61 | 06-04-17 |
Emil Kakkis
FOU | Founder | 63 | 22-04-10 |
Daniel Welch
CHM | Chairman | 66 | 08-04-15 |
Matthew Fust
BRD | Director/Board Member | 59 | 01-01-14 |
Michael Narachi
BRD | Director/Board Member | 64 | 20-02-15 |
Corazon Sanders
BRD | Director/Board Member | 67 | 29-06-21 |
Shehnaaz Suliman
BRD | Director/Board Member | 52 | 30-01-19 |
Amrit Ray
BRD | Director/Board Member | 51 | 19-04-22 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 82 345 246 | 78 952 476 ( 95,88 %) | 9 559 ( 0,0116 %) | 95,88 % |
Bedrijfsgegevens
Sector
Verkoop per activiteit
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-5,08% | 3,6 mld. | |
-0,60% | 103 mld. | |
+3,39% | 96,73 mld. | |
+1,66% | 21,31 mld. | |
-16,36% | 21,21 mld. | |
-6,82% | 18,79 mld. | |
-41,41% | 16,37 mld. | |
-23,86% | 13,68 mld. | |
+5,86% | 13,44 mld. | |
+22,43% | 10,98 mld. |
- Beurs
- Aandelen
- Koers RARE
- Onderneming Ultragenyx Pharmaceutical Inc.